Astria Therapeutics, Inc.
ATXSDelisted Jan 23, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001454789
Astria Therapeutics, Inc. was delisted on Jan 23, 2026; its insiders filed their last Form 4 on Jan 23, 2026; 141 institutions reported holding it in 13F filings for Q4 2025, worth $738.2M in total; Soros Fund Management was the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Astria Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 100 | 2 | 103 | +5 |
| Shares | 55.6M | 3.56M | 56.5M | +4.50M (+8.6%) |
| Value | $505.8M | $32.4M | $622.1M | +$148.7M (+31.4%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Astria Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 3,499,478 | $38.5M | 0.00% |
| Redmile Group, LLC | 310,884 | $3.42M | 0.20% |
| Schonfeld Strategic Advisors LLC | 79,205 | $872.0K | 0.01% |
| Swiss National Bank | 58,900 | $648.5K | 0.00% |
| StemPoint Capital LP | 56,287 | $618.9K | 0.19% |
| UBS Asset Management Americas Inc | 55,696 | $613.2K | 0.00% |
| Patient Square Capital LP | 39,422 | $434.0K | 0.16% |
| American Century Companies Inc | 38,854 | $427.8K | 0.00% |
| Intech Investment Management LLC | 20,665 | $227.5K | 0.00% |
| SG Americas Securities, LLC | 14,078 | $155.0K | 0.00% |
| PDT Partners, LLC | 12,749 | $140.4K | 0.01% |
| Deerfield Management Company, L.P. (Series C) | 12,153 | $133.8K | 0.00% |
| Acadian Asset Management LLC | 2,411 | $26.0K | 0.00% |
| nVerses Capital, LLC | 800 | $8.81K | 0.00% |
| Russell Investments Group, Ltd. | 385 | $4.24K | 0.00% |
| Sterling Capital Management LLC | 60 | $661 | 0.00% |
Sold out (11)
Institutions that held Astria Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Cubist Systematic Strategies, LLC | 281,410 | $2.56M |
| Squarepoint Ops LLC | 201,210 | $1.83M |
| Jump Financial, LLC | 68,697 | $625.1K |
| Polar Asset Management Partners Inc. | 56,300 | $512.3K |
| Balyasny Asset Management LLC | 50,776 | $462.1K |
| Panagora Asset Management Inc | 30,926 | $281.4K |
| Engineers Gate Manager LP | 13,064 | $118.9K |
| CoreCap Advisors, LLC | 2,000 | $18.2K |
| Point72 (DIFC) Ltd | 857 | $7.80K |
| Pacer Advisors, Inc. | 613 | $5.58K |
| Macquarie Group Ltd | 219 | $1.99K |
Not filed for Q3 2024 yet (2)
Institutions that held Astria Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 3,517,580 | $32.0M |
| Susquehanna Fundamental Investments, LLC | 44,000 | $400.4K |